vs
COFFEE HOLDING CO INC（JVA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是COFFEE HOLDING CO INC的1.1倍（$30.3M vs $27.7M），COFFEE HOLDING CO INC净利率更高（2.9% vs -221.3%，领先224.3%），REGENXBIO Inc.同比增速更快（43.0% vs 30.8%），COFFEE HOLDING CO INC自由现金流更多（$265.4K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 19.2%）
黑步枪咖啡公司是一家总部位于美国犹他州盐湖城的咖啡企业，由前美国陆军绿色贝雷帽成员埃文·黑弗于2014年创立。2017年，该公司因回应星巴克招聘一万名难民的承诺，宣布将招聘一万名退伍军人而受到全美国关注。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
JVA vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$27.7M
营收增速更快
RGNX
高出12.2%
30.8%
净利率更高
JVA
高出224.3%
-221.3%
自由现金流更多
JVA
多$53.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
19.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $27.7M | $30.3M |
| 净利润 | $811.5K | $-67.1M |
| 毛利率 | 8.5% | — |
| 营业利润率 | 2.8% | -190.0% |
| 净利率 | 2.9% | -221.3% |
| 营收同比 | 30.8% | 43.0% |
| 净利润同比 | -35.7% | -31.2% |
| 每股收益（稀释后） | $0.15 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JVARGNX
| Q4 25 | $27.7M | $30.3M | ||
| Q3 25 | $23.9M | $29.7M | ||
| Q2 25 | $23.3M | $21.4M | ||
| Q1 25 | $21.3M | $89.0M | ||
| Q4 24 | $21.2M | $21.2M | ||
| Q3 24 | $18.8M | $24.2M | ||
| Q2 24 | $19.0M | $22.3M | ||
| Q1 24 | $19.5M | $15.6M |
净利润JVARGNX
| Q4 25 | $811.5K | $-67.1M | ||
| Q3 25 | $-1.2M | $-61.9M | ||
| Q2 25 | $644.1K | $-70.9M | ||
| Q1 25 | $1.2M | $6.1M | ||
| Q4 24 | $1.3M | $-51.2M | ||
| Q3 24 | $626.8K | $-59.6M | ||
| Q2 24 | $-21.8K | $-53.0M | ||
| Q1 24 | $351.0K | $-63.3M |
毛利率JVARGNX
| Q4 25 | 8.5% | — | ||
| Q3 25 | 12.2% | — | ||
| Q2 25 | 18.9% | — | ||
| Q1 25 | 26.9% | — | ||
| Q4 24 | 23.2% | 70.2% | ||
| Q3 24 | 20.9% | 48.8% | ||
| Q2 24 | 19.5% | 52.5% | ||
| Q1 24 | 17.8% | 72.6% |
营业利润率JVARGNX
| Q4 25 | 2.8% | -190.0% | ||
| Q3 25 | -4.6% | -176.3% | ||
| Q2 25 | 3.8% | -296.3% | ||
| Q1 25 | 7.5% | 13.6% | ||
| Q4 24 | 8.0% | -242.1% | ||
| Q3 24 | 3.8% | -256.6% | ||
| Q2 24 | -0.4% | -251.3% | ||
| Q1 24 | 3.2% | -408.8% |
净利率JVARGNX
| Q4 25 | 2.9% | -221.3% | ||
| Q3 25 | -5.0% | -208.3% | ||
| Q2 25 | 2.8% | -331.8% | ||
| Q1 25 | 5.4% | 6.8% | ||
| Q4 24 | 5.9% | -241.3% | ||
| Q3 24 | 3.3% | -246.3% | ||
| Q2 24 | -0.1% | -237.7% | ||
| Q1 24 | 1.8% | -405.4% |
每股收益（稀释后）JVARGNX
| Q4 25 | $0.15 | $-1.30 | ||
| Q3 25 | $-0.21 | $-1.20 | ||
| Q2 25 | $0.11 | $-1.38 | ||
| Q1 25 | $0.20 | $0.12 | ||
| Q4 24 | $0.22 | $-0.99 | ||
| Q3 24 | $0.11 | $-1.17 | ||
| Q2 24 | $0.00 | $-1.05 | ||
| Q1 24 | $0.06 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $701.9K | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $27.6M | $102.7M |
| 总资产 | $42.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JVARGNX
| Q4 25 | $701.9K | $230.1M | ||
| Q3 25 | $979.8K | $274.2M | ||
| Q2 25 | $1.8M | $323.3M | ||
| Q1 25 | $2.4M | $267.9M | ||
| Q4 24 | $1.4M | $234.7M | ||
| Q3 24 | $3.1M | $255.5M | ||
| Q2 24 | $2.4M | $290.4M | ||
| Q1 24 | $2.4M | $338.7M |
股东权益JVARGNX
| Q4 25 | $27.6M | $102.7M | ||
| Q3 25 | $26.8M | $161.5M | ||
| Q2 25 | $28.0M | $213.7M | ||
| Q1 25 | $27.3M | $274.2M | ||
| Q4 24 | $26.2M | $259.7M | ||
| Q3 24 | $24.9M | $301.4M | ||
| Q2 24 | $24.3M | $348.3M | ||
| Q1 24 | $24.3M | $390.7M |
总资产JVARGNX
| Q4 25 | $42.0M | $453.0M | ||
| Q3 25 | $45.9M | $525.2M | ||
| Q2 25 | $39.7M | $581.0M | ||
| Q1 25 | $38.9M | $490.9M | ||
| Q4 24 | $34.0M | $466.0M | ||
| Q3 24 | $33.1M | $519.1M | ||
| Q2 24 | $34.9M | $569.4M | ||
| Q1 24 | $37.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $377.7K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $265.4K | $-52.8M |
| 自由现金流率自由现金流/营收 | 1.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.47× | — |
| 过去12个月自由现金流最近4个季度 | $-5.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流JVARGNX
| Q4 25 | $377.7K | $-52.3M | ||
| Q3 25 | $-3.8M | $-56.0M | ||
| Q2 25 | $-1.2M | $-49.3M | ||
| Q1 25 | $-401.9K | $33.6M | ||
| Q4 24 | $222.0K | $-31.6M | ||
| Q3 24 | $1.8M | $-40.5M | ||
| Q2 24 | $-1.2M | $-45.5M | ||
| Q1 24 | $4.6M | $-55.5M |
自由现金流JVARGNX
| Q4 25 | $265.4K | $-52.8M | ||
| Q3 25 | $-3.9M | $-56.5M | ||
| Q2 25 | $-1.2M | $-49.7M | ||
| Q1 25 | $-419.8K | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $1.8M | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率JVARGNX
| Q4 25 | 1.0% | -174.0% | ||
| Q3 25 | -16.3% | -189.9% | ||
| Q2 25 | -5.0% | -232.8% | ||
| Q1 25 | -2.0% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | 9.4% | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度JVARGNX
| Q4 25 | 0.4% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率JVARGNX
| Q4 25 | 0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.79× | — | ||
| Q1 25 | -0.35× | 5.53× | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 2.90× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 13.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JVA
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
